Better Buy for the Second Half: Celsius Down 36% or a 50/50 Split of Coca-Cola and Pepsi?

Celsius Holdings (CELH) is down about 36% in 2026 as its flagship brand loses momentum, despite building an energy-drink portfolio via Alani Nu and Rockstar. The article argues Coca-Cola and PepsiCo are absorbing the same “better-for-you” prebiotic/gut-health trend (e.g., Coke’s Simply Pop; Pepsi’s Poppi/Pepsi Prebiotic Cola and reformulations), reducing the valuation appeal of Celsius as a disruptor. It recommends a 50/50 split into KO and PEP for diversification and steady dividend growth, while noting PepsiCo also has a stake and distribution ties to Celsius—so energy upside is partially captured with less volatility.

Analysis

This is less a verdict on energy drinks than a valuation reset around who owns the health-and-functionality shelf. CELH’s problem is concentration: when a growth story depends on a single flagship regaining velocity while two acquired brands absorb the load, any channel slowdown gets amplified into multiple compression. The more important second-order effect is that shelf space is not infinite; if KO and PEP keep scaling prebiotic and reduced-sugar offerings, they can crowd out smaller challengers without needing to win the category outright.

PEP looks like the cleaner relative-value winner because it captures the same trend with an embedded option on CELH through distribution and ownership exposure, while KO has the stronger pure-brand operating leverage if the market re-rates “better-for-you” as a durable subcategory rather than a fad. The main near-term catalyst is not consumer demand in aggregate but retailer resets and distributor priorities over the next 1-3 months; that’s where CELH can lose incremental facings fastest if sell-through disappoints. Over 6-18 months, the structural risk for CELH is that incumbents turn functional beverages into another scale game, which would cap terminal margins and keep the stock in a low-confidence multiple band.

Contrarianly, the selloff in CELH may already price in a lot of core-brand fatigue, so the asymmetric question is whether the market is underestimating international expansion or a successful relaunch cycle. Still, until there is evidence of sustained core-brand reacceleration, the burden of proof sits with CELH. For KO/PEP, the consensus may be overpaying for defensiveness if volume growth remains modest and investors only get dividend support rather than meaningful top-line surprise.

Key Decisions for Investors

• Preferred relative-value trade: long PEP / short CELH for 3-6 months; thesis is that PEP monetizes the health-beverage trend with lower earnings volatility, while CELH remains exposed to core-brand deceleration and portfolio integration risk. Falsify if CELH reaccelerates core U.S. sales or PEP guidance misses on beverage mix.
• If wanting outright exposure, buy PEP over KO on pullbacks; PEP has the cleaner embedded optionality to CELH and broader category exposure, while KO needs more multiple expansion to outperform. Target is modest outperformance rather than absolute alpha; exit if PEP loses distributor momentum or margin guidance deteriorates.
• Avoid initiating new CELH longs until channel data confirm restoration of core SKU velocity and not just acquired-brand growth. Watch for 1-2 quarter proof, not press-release claims; if sell-through improves, downside risk to CELH could narrow sharply, but without that, risk/reward remains poor.
• For lower-volatility capital deployment, use a staged entry into KO/PEP rather than a full allocation now; the trade is essentially being paid via dividends while waiting for the better-for-you category to prove it has staying power. Falsify if defensive beverage multiples contract despite stable earnings.